[go: up one dir, main page]

DE69407758D1 - Antikörper zur behandlung von insulinabhängigen diabetes - Google Patents

Antikörper zur behandlung von insulinabhängigen diabetes

Info

Publication number
DE69407758D1
DE69407758D1 DE69407758T DE69407758T DE69407758D1 DE 69407758 D1 DE69407758 D1 DE 69407758D1 DE 69407758 T DE69407758 T DE 69407758T DE 69407758 T DE69407758 T DE 69407758T DE 69407758 D1 DE69407758 D1 DE 69407758D1
Authority
DE
Germany
Prior art keywords
antibodies
dependent diabetes
treating insulin
diabetes
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69407758T
Other languages
English (en)
Other versions
DE69407758T3 (de
DE69407758T2 (de
Inventor
Linda Burkly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21848497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69407758(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of DE69407758D1 publication Critical patent/DE69407758D1/de
Application granted granted Critical
Publication of DE69407758T2 publication Critical patent/DE69407758T2/de
Publication of DE69407758T3 publication Critical patent/DE69407758T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69407758T 1993-02-09 1994-02-09 Antikörper zur behandlung von insulinabhängigem diabetes Expired - Lifetime DE69407758T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2933093A 1993-02-09 1993-02-09
US29330 1993-02-09
PCT/US1994/001456 WO1994017828A2 (en) 1993-02-09 1994-02-09 Treatment for insulin dependent diabetes

Publications (3)

Publication Number Publication Date
DE69407758D1 true DE69407758D1 (de) 1998-02-12
DE69407758T2 DE69407758T2 (de) 1998-08-27
DE69407758T3 DE69407758T3 (de) 2007-05-24

Family

ID=21848497

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69407758T Expired - Lifetime DE69407758T3 (de) 1993-02-09 1994-02-09 Antikörper zur behandlung von insulinabhängigem diabetes

Country Status (13)

Country Link
US (2) US5888507A (de)
EP (1) EP0682529B2 (de)
JP (1) JP3593343B2 (de)
AT (1) ATE161730T1 (de)
AU (1) AU687790B2 (de)
CA (1) CA2155303C (de)
DE (1) DE69407758T3 (de)
DK (1) DK0682529T4 (de)
ES (1) ES2114183T5 (de)
GR (1) GR3026531T3 (de)
HK (1) HK1008731A1 (de)
NZ (1) NZ262615A (de)
WO (1) WO1994017828A2 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843438A (en) 1992-11-13 1998-12-01 Board Of Regents University Of Washington Peripheralization of hematopoietic stem cells
CA2153692C (en) * 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
HK1008731A1 (en) * 1993-02-09 1999-05-14 Biogen Idec Ma Inc. Antibody for the treatment of insulin dependent diabetes
US5677291A (en) * 1993-12-10 1997-10-14 Hoechst Marion Roussel, Inc. Method of lowering serum cholesterol levels with 2,6-di-alkyl-4-silyl-phenols
US5750336A (en) * 1994-02-10 1998-05-12 The Salk Institute For Biological Studies Assays for the identification of compounds which inhibit activation of cAMP and mitogen responsive genes
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US5795876A (en) * 1996-04-30 1998-08-18 Hoechst Marion Rousssel, Inc. Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2, 6-di-alkyl-4-silyl-phenols
US5608095A (en) * 1996-04-30 1997-03-04 Hoechst Marion Roussel, Inc. Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6114572A (en) * 1996-11-20 2000-09-05 Hoechst Marion Roussel, Inc. Substituted phenols and thiophenols useful as antioxidant agents
EA199900947A1 (ru) * 1997-04-18 2000-04-24 Байоджен, Инк. Гибридные белки tgf-бета ii типа/константной области иммуноглобулина
US6121463A (en) * 1997-06-24 2000-09-19 Hoechst Marion Roussel, Inc. Alkyl-4-silylheterocyclic phenols and thiophenols useful as antioxidant agents
US6133467A (en) * 1997-06-25 2000-10-17 Hoechst Marion Roussel, Inc. 2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)-methyl-oxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxy-phenylsilyl)methyloxy]phenol
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
IL141877A0 (en) 1998-09-14 2002-03-10 Biogen Inc Pharmaceutical compositions containing alpha4 integrin antagonists
US7618630B2 (en) * 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US6110109A (en) * 1999-03-26 2000-08-29 Biosignia, Inc. System and method for predicting disease onset
GEP20063844B (en) 1999-04-22 2006-06-12 Biogen Idec Inc Using antagonist of integrin alpha-4 subunit for treatment of fibrosis
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
GEP20063774B (en) 1999-06-01 2006-03-27 Biogen Idec Inc Blocking Monoclonal Antibody to VLA-1 and Its Use for Treatment of Inflammatory Disorders
AU783266B2 (en) * 1999-09-14 2005-10-06 Biogen Ma Inc. Therapies for chronic renal failure using one or more integrin antagonists
CN100475953C (zh) 1999-12-06 2009-04-08 通用医疗公司 胰腺干细胞
WO2001043774A1 (en) 1999-12-16 2001-06-21 Biogen, Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
US20060115473A1 (en) * 2000-12-14 2006-06-01 Biogen Idec Ma Inc., A Massachusetts Corporation Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
JP3459609B2 (ja) * 2000-03-17 2003-10-20 三洋電機株式会社 ライトキャッシュ回路、ライトキャッシュ回路を備えた記録装置、およびライトキャッシュ方法
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
CZ303450B6 (cs) 2001-04-13 2012-09-19 Biogen Idec Ma Inc. Protilátky k VLA-1, kompozice je obsahující a nukleové kyseliny, které je kódují, zpusob stanovení hladiny VLA-1 a použití pri lécení imunologického onemocnení
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
EP1592387A4 (de) 2003-01-24 2009-05-06 Elan Pharm Inc Zusammensetzung für und behandlung von entmyelinierenden erkrankungen und paralyse durch verabreichung von remyelinierenden mitteln
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
AU2005306399B2 (en) 2004-11-19 2012-02-09 Biogen Ma Inc. Treatment for multiple sclerosis
US20090169477A1 (en) * 2004-12-03 2009-07-02 Michael Panzara Delaying or preventing onset of multiple sclerosis
LT2645106T (lt) * 2005-04-04 2017-09-11 Biogen Ma Inc. Imuninio atsako į terapinį agentą įvertinimo būdai
WO2007061679A1 (en) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN
JP5496658B2 (ja) 2006-05-25 2014-05-21 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脳卒中を処置する方法
MX2009013593A (es) * 2007-06-14 2010-01-20 Biogen Idec Inc Formulaciones de anticuerpos.
US9233107B2 (en) 2007-09-14 2016-01-12 Biogen Ma Inc. Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (PML)
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
JP2013525260A (ja) * 2009-04-17 2013-06-20 バイオジェン・アイデック・エムエイ・インコーポレイテッド 急性骨髄性白血病を治療するための組成物および方法
EP2467159A1 (de) 2009-08-20 2012-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Vla-4 als biomarker zur prognose und target zur behandlung der duchenne-muskeldystrophie
AU2010303156B2 (en) 2009-10-11 2016-02-04 Biogen Ma Inc. Anti-VLA-4 related assays
BR112012026403B1 (pt) 2010-04-16 2022-10-04 Biogen Ma Inc Molécula de anticorpo recombinante ou um fragmento de ligação a ?4 da mesma e seu uso
LT3326645T (lt) 2010-10-25 2020-08-10 Biogen Ma Inc. Alfa-4 integrino aktyvumo skirtumų, koreliuojant su skirtumais svcam ir (arba) smadcam lygiuose, nustatymo būdai
SMT201700515T1 (it) 2011-05-02 2018-01-11 Millennium Pharm Inc Formulazione per anticorpo anti- 4 7
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN104271122A (zh) 2012-02-16 2015-01-07 桑塔鲁斯股份有限公司 抗vla1(cd49a)抗体药物组合物
EP2828284B1 (de) 2012-03-20 2019-05-08 Biogen MA Inc. Jcv-neutralisierende antikörper
EP2845134A1 (de) 2012-04-20 2015-03-11 Biogen Idec MA Inc. Zusammengesetzte kognitive parameter und verwendungen davon zur bewertung von multipler sklerose
EP2849787A4 (de) 2012-05-14 2016-06-15 Biogen Ma Inc Lingo-2 antagonisten zur behandlung von erkrankungen mit beteiligung von motorneuronen
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
WO2014028299A1 (en) 2012-08-13 2014-02-20 Biogen Idec Ma Inc. Disease progression parameters and uses thereof for evaluating multiple sclerosis
JP2015534564A (ja) 2012-10-09 2015-12-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 脱髄障害の治療のための併用療法および使用
WO2015063604A2 (en) 2013-11-01 2015-05-07 Imberti Luisa BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNβ AND USES THEREOF
MX2017009038A (es) 2015-01-08 2017-10-25 Biogen Ma Inc Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
AU2016270373A1 (en) 2015-06-05 2018-01-04 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
CN109862911A (zh) 2016-07-13 2019-06-07 比奥根Ma公司 Lingo-1拮抗剂的剂量方案和用于治疗脱髓鞘病症的用途
WO2018045162A1 (en) 2016-09-01 2018-03-08 Biogen Ma Inc. Biomarkers predictive of primary progressive multiple sclerosis and uses thereof
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
CN119080931A (zh) 2018-06-04 2024-12-06 马萨诸塞州渤健公司 具有降低的效应功能的抗vla-4抗体
AU2020234943A1 (en) 2019-03-11 2021-09-23 Biogen Ma Inc. Pharmaceutical compositions containing anti-LINGO-1 antibodies
WO2022162164A1 (en) 2021-01-29 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US5053393A (en) * 1988-07-20 1991-10-01 Monsanto Company Novel platelet-aggregation inhibitor
US4879313A (en) * 1988-07-20 1989-11-07 Mosanto Company Novel platelet-aggregation inhibitors
CA2002860A1 (en) * 1988-11-14 1990-05-14 Michael A. Gimbrone Antibodies specific for elam-1 and the use thereof
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5217870A (en) * 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US5061693A (en) * 1989-07-28 1991-10-29 Merck & Co., Inc. Fibrinogen receptor antagonists
IL113261A (en) † 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
US4952562A (en) * 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
US5053392A (en) * 1989-12-01 1991-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Novel arginine, glycine, aspartic acid derivatives as platelet-aggregation inhibitors
US5260277A (en) * 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1993008823A1 (en) * 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1993013798A1 (en) * 1992-01-13 1993-07-22 Biogen, Inc. Treatment for asthma
ATE151642T1 (de) * 1992-02-12 1997-05-15 Biogen Inc Behandlung für entzündungserkrankung des darmes
US5843438A (en) * 1992-11-13 1998-12-01 Board Of Regents University Of Washington Peripheralization of hematopoietic stem cells
US5591719A (en) * 1992-12-10 1997-01-07 Regents Of The University Of Minnesota Method for treating acute and chronic inflammatory disorders using polypeptides with fibronectin activity
CA2153692C (en) * 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
HK1008731A1 (en) * 1993-02-09 1999-05-14 Biogen Idec Ma Inc. Antibody for the treatment of insulin dependent diabetes
KR100367948B1 (ko) * 1994-01-25 2003-07-12 엘란 파마슈티칼스, 인크. 백혈구부착분자vla-4에대한인체화된항체

Also Published As

Publication number Publication date
US20050208053A1 (en) 2005-09-22
JP3593343B2 (ja) 2004-11-24
US5888507A (en) 1999-03-30
ES2114183T3 (es) 1998-05-16
WO1994017828A2 (en) 1994-08-18
DK0682529T4 (da) 2006-05-15
EP0682529B2 (de) 2005-12-28
DE69407758T3 (de) 2007-05-24
DK0682529T3 (da) 1998-09-07
EP0682529B1 (de) 1998-01-07
CA2155303C (en) 2010-04-20
WO1994017828A3 (en) 1994-10-13
AU687790B2 (en) 1998-03-05
ATE161730T1 (de) 1998-01-15
GR3026531T3 (en) 1998-07-31
NZ262615A (en) 1996-02-27
JPH08508719A (ja) 1996-09-17
HK1008731A1 (en) 1999-05-14
AU6237994A (en) 1994-08-29
CA2155303A1 (en) 1994-08-18
ES2114183T5 (es) 2006-06-16
EP0682529A1 (de) 1995-11-22
DE69407758T2 (de) 1998-08-27

Similar Documents

Publication Publication Date Title
ATE161730T1 (de) Antikörper zur behandlung von insulinabhängigen diabetes
ATE150319T1 (de) Behandlung von asthma
DE58905835D1 (de) Vorrichtung zur nadellosen, subkutanen Injektion von Medikamenten.
FI89032C (fi) Propp
EA199800316A1 (ru) СЕЛЕКТИВНЫЕ β-АДРЕНЕРГИЧЕСКИЕ АГОНИСТЫ
DK0703788T3 (da) Stabiliseret phenylalaninammoniaklyase
DE69838147D1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
DE69020143D1 (de) Verfahren zur verwendung und herstellung von peptiden.
ATE180408T1 (de) Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
DK0673255T3 (da) Monoklonale antistoffer, som specifikt binder til vaskulært tumorendotel, og anvendelser deraf
ATE177758T1 (de) Synthetische peptide, antikörper dagegen und ihre verwendung
DK0430200T3 (da) Polypeptidholdigt lægemiddel til subkutan eller intramuskulær applikation
BR9809656A (pt) Composição imunopotencializante
BG101392A (en) Method of treating diabetes mellitus using kgf
HUP9900935A2 (hu) Baktériumellenes és gombaellenes hatású peptid és eljárás az előállítására
DK0552240T3 (da) Ny metode til behandling af depression
WO1999016791A3 (en) Compounds and methods for regulating cell adhesion
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
DE69133068D1 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
MX9702152A (es) Clonacion de una aminopeptidasa de membrana, dependiente de la insulina, a partir de vesiculas de glut-4.
EP1412388A4 (de) Von dd 3b6/22 abgeleitete humanisierte antikörper mit spezifität für das d-dimer fragment von fibrin
UA32522C2 (uk) Ліофілізована протипухлинна композиція і стерильна водна композиція для ін'єкцій на її основі
ATE114713T1 (de) Biomasse zur produktion von virus/virusantigen.
EP0253325A3 (de) Von Onkogenen abgeleitete Peptide
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: BIOGEN IDEC MA INC., CAMBRIDGE, MASS., US